Bacteriophage therapy of urinary tract infections
Abstract
The search for antibiotic alternatives, due to the growing level of antibiotic resistant microorganisms against the background of a decrease in the development and introduction of new antibiotics, draws our attention to bacteriophages (phages). The chapter briefly presents the history of bacteriophage therapy (phage therapy), the principles of phage treatment, modern knowledge about genetically engineered phages, phage lytic proteins – lysine and endolysins. Prospects of using phages in treatment of biofilm infection and joint use of phages and antibiotics are given. The mechanisms of resistance of bacteria to phages, the kinetics of phages in the human body during oral and rectal administration are described. Studies on the clinical use of phages are given, the problems of phage therapy and further prospects for the use of phages are discussed.
Read the paper
Related studies
- Horizontal gene transfer in the human gastrointestinal tract: potential spread of antibiotic resistance genes
- Mutation supply and relative fitness shape the genotypes of ciprofloxacin-resistant Escherichia coli
- Genomic Survey of E. coli From the Bladders of Women With and Without Lower Urinary Tract Symptoms
- Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017–18
- Fitness cost constrains the spectrum of marR mutations in ciprofloxacin-resistant Escherichia coli
- Emerging evidence-based innovative approaches to control catheter-associated urinary tract infection: a review
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.